Skip header and navigation

Refine By

5 records – page 1 of 1.

Early death and CSF monoamine metabolites in schizophrenia spectrum psychosis.

https://arctichealth.org/en/permalink/ahliterature141897
Source
Nord J Psychiatry. 2011 Apr;65(2):101-5
Publication Type
Article
Date
Apr-2011
Author
Andreas Carlborg
Jussi Jokinen
Anna-Lena Nordström
Erik G Jönsson
Peter Nordström
Author Affiliation
Department of Clinical Neuroscience, Psychiatry, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden. andreas.carlborg@sll.se
Source
Nord J Psychiatry. 2011 Apr;65(2):101-5
Date
Apr-2011
Language
English
Publication Type
Article
Keywords
Adult
Age Factors
Cause of Death
Cerebrospinal Fluid - metabolism
Female
Follow-Up Studies
Homovanillic Acid - cerebrospinal fluid
Humans
Hydroxyindoleacetic Acid - cerebrospinal fluid
Male
Middle Aged
Predictive value of tests
Risk factors
Schizophrenia - metabolism - mortality
Schizophrenic Psychology
Sweden
Young Adult
Abstract
Patients with schizophrenia have higher rates of mortality than the general population. Lower concentrations of the cerebrospinal fluid (CSF) monoamine metabolites homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) have been associated with suicidal, aggressive and impulsive behavior. Mortality has been suggested as a measure of impulsivity and a relationship between early death and lower concentrations of CSF monoamine metabolites has been reported but the studies are few with short periods of follow-up and small numbers.
The objective of this study was to investigate a relationship between early death and concentrations of CSF 5-HIAA and HVA.
Three hundred and eighty-five inpatients with schizophrenia spectrum psychosis were lumbar punctured in a standardized manner and followed for a median of 26 years. Patients were searched to identify those who had died. Causes of death were obtained from the Causes of Death Register.
During the time of follow-up, 97 patients died. Schizophrenia spectrum psychosis patients died at an earlier age from both natural and unnatural causes of death. No significant associations were found between CSF 5-HIAA and HVA concentrations and non-suicidal death. Attempted suicide was not a risk factor for non-suicidal death at younger age.
Patients with schizophrenia spectrum psychosis die at an earlier age from both natural and unnatural causes of death. Attempted suicide is not a risk factor for non-suicidal death at younger age. Low concentrations of CSF HVA and 5-HIAA were not a risk factor for non-suicidal death at younger age in schizophrenia spectrum psychosis.
PubMed ID
20662686 View in PubMed
Less detail

[Internship-test reveals increased knowledge gaps].

https://arctichealth.org/en/permalink/ahliterature279766
Source
Lakartidningen. 2016 04 08;113
Publication Type
Article
Date
04-08-2016
Author
Carl-Johan Östgren
Margareta Krook-Brandt
Andreas Carlborg
Source
Lakartidningen. 2016 04 08;113
Date
04-08-2016
Language
Swedish
Publication Type
Article
Keywords
Clinical Competence - standards
Educational Measurement - statistics & numerical data
European Union
Foreign Medical Graduates - standards
Humans
Internship and Residency - standards
Licensure, Medical - standards
Sweden
Abstract
We present the results of the medical knowledge test after fulfilled internship for Swedish medical authorization during the years 2009 to the spring of 2015. A total of 7,613 tests were analyzed. Interns graduated from Swedish universities failed in 2.7% to 3.8% of the test moments. Interns who graduated from countries within the European Union (EU) failed in 21.2% and interns graduated from a non-EU country failed in 41.6%. The results from those who graduated from EU and non-EU countries have worsened compared to an earlier study in 2009. Proper measures have now to be implemented for doctors graduated from a non-Swedish university to improve the outcome and introduction to the Swedish health care system.
PubMed ID
27070392 View in PubMed
Less detail

Patient preferences for medicine administration for acute agitation: results from an internet-based survey of patients diagnosed with bipolar disorder or schizophrenia in two Nordic countries.

https://arctichealth.org/en/permalink/ahliterature292122
Source
Psychol Health Med. 2018 Jan; 23(1):30-38
Publication Type
Journal Article
Date
Jan-2018
Author
Tine Rikke Jørgensen
Charlotte Emborg
Karianne Dahlen
Mette Bøgelund
Andreas Carlborg
Author Affiliation
a Janssen-Cilag , Birkerød , Denmark.
Source
Psychol Health Med. 2018 Jan; 23(1):30-38
Date
Jan-2018
Language
English
Publication Type
Journal Article
Keywords
Adult
Antipsychotic Agents - administration & dosage
Bipolar Disorder - drug therapy
Denmark
Drug Administration Routes
Female
Humans
Internet
Loxapine
Male
Middle Aged
Patient Preference
Psychomotor Agitation - drug therapy
Schizophrenia - drug therapy
Surveys and Questionnaires
Sweden
Young Adult
Abstract
The objective was to elicit patient preferences for medicine administration method in the management of acute agitation episodes among patients diagnosed with bipolar disorder or schizophrenia. The patients' experiences of acute agitation episodes and their management of episodes were also explored. Data were collected via an anonymous, internet-based survey of residents in Denmark or Sweden with schizophrenia or bipolar disorder (October 2014 to December 2014). Inclusion criteria were having a diagnosis of schizophrenia or bipolar disorder, and being above 18 years of age. The questionnaire included questions about preferences for medication attributes, experiences with pharmacological treatment for agitation and involvement in treatment plans. A total of 237 diagnosed patients (61 with schizophrenia; 176 with bipolar disorder) completed the questionnaire. Agitation episodes were experienced by 90% of the respondents. In total, 83% of the respondents reported having received treatment with tablets. When patients were presented with the attributes of an inhalation method, respondents stated that the fast onset of action, low risk of adverse reactions and least invasive form of drug delivery were positive attributes of treatment with inhalation. Inhalation is a new delivery route for treatment of acute agitation in patients diagnosed with bipolar disorder or schizophrenia. Inhalation is the preferred treatment method for acute agitation among Danish and Swedish patients with bipolar disorder or schizophrenia.
PubMed ID
28475360 View in PubMed
Less detail

Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study.

https://arctichealth.org/en/permalink/ahliterature272134
Source
Bipolar Disord. 2015 Feb;17(1):76-85
Publication Type
Article
Date
Feb-2015
Author
Andreas Carlborg
Lena Ferntoft
Marcus Thuresson
Johan Bodegard
Source
Bipolar Disord. 2015 Feb;17(1):76-85
Date
Feb-2015
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antidepressive Agents - therapeutic use
Bipolar Disorder - diagnosis - mortality - psychology - therapy
Comorbidity
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Patient Care Management - trends
Prevalence
Registries
Retrospective Studies
Socioeconomic Factors
Spatio-Temporal Analysis
Sweden - epidemiology
Abstract
The aim of the study was to describe temporal changes in bipolar disorder during 20 years within the Swedish population and to investigate clinical and socioeconomic characteristics, drug treatment, and mortality among patients with bipolar disorder.
We conducted a retrospective, nationwide registry study (the Swedish Population Register) that included all patients diagnosed with bipolar disorder (1991-2010) and linked individual data from the Swedish National Patient Register, the National Prescribed Drug Register, and the Population Register (NCT01455961). A cross-sectional cohort analysis was performed for years 2006 versus 2009. Data were analyzed using descriptive statistics.
During the study period, the annual incidence of diagnosed bipolar disorder increased 3.5-fold, and patients were diagnosed at a younger age. Mortality among patients with bipolar disorder was twice that of the general population. Compared to an age-standardized population, 30% fewer patients with bipolar disorder were available for work. Among the 40% employed, 64% reported sick leave (46% >100 days/year). Despite similar education levels, disposable income was lower compared to the general population. The most commonly preceding psychiatric diagnoses were depressive or anxiety disorders. Comparing the data for 2006 and 2009 demonstrated similar somatic comorbidity burdens and socioeconomic levels. There was also a decrease in dispensed antipsychotic medications and lithium, while antiepileptic prescriptions increased slightly. Antidepressant dispenses remained virtually unchanged.
In Sweden, the incidence and prevalence of diagnosed bipolar disorder have increased during the last 20 years. Compared to the general population, these patients had similar education levels, lower employment levels, less disposable income, more sick leave, and twice the mortality. A trend towards earlier diagnosis, more use of antidepressants, and less use of lithium was seen.
PubMed ID
25056132 View in PubMed
Less detail

A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark.

https://arctichealth.org/en/permalink/ahliterature120500
Source
Hum Psychopharmacol. 2012 Sep;27(5):492-8
Publication Type
Article
Date
Sep-2012
Author
Charlotte Emborg
Teresa Hallerbäck
Leif Jörgensen
Andreas Carlborg
Author Affiliation
OPUS Klinikken, Risskov, Denmark. chaembor@rm.dk
Source
Hum Psychopharmacol. 2012 Sep;27(5):492-8
Date
Sep-2012
Language
English
Publication Type
Article
Keywords
Adult
Antipsychotic Agents - administration & dosage - therapeutic use
Delayed-Action Preparations
Denmark
Dibenzothiazepines - administration & dosage - therapeutic use
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Outpatients
Retrospective Studies
Schizophrenia - drug therapy
Young Adult
Abstract
The atypical antipsychotic quetiapine is a first-line treatment for schizophrenia. This non-interventional study (NCT01212575) evaluated the clinical use of its two formulations, extended release (XR) and immediate release (IR), in outpatients with schizophrenia spectrum disorder.
Patients who had received at least one dose of quetiapine XR and/or IR were included. A dosage =400?mg/day was defined as antipsychotic. Medical records data were collected retrospectively.
Of 186 enrolled patients, 99 (53%) and 87 (47%) received quetiapine XR and IR, respectively. Use in antipsychotic dosage was seen for 89% XR versus 63% IR patients (mean daily dose =400?mg/day; p?
Notes
Cites: J Clin Psychiatry. 1999;60 Suppl 23:14-910625195
Cites: CNS Drugs. 2011 May;25(5):383-9921476610
Cites: Nord J Psychiatry. 2003;57(4):263-912888400
Cites: Int Clin Psychopharmacol. 2004 Sep;19(5):281-915289701
Cites: Arch Gen Psychiatry. 2005 Mar;62(3):247-5315753237
Cites: BMJ. 2005 Sep 17;331(7517):60216141449
Cites: Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S156-6216872807
Cites: J Clin Psychiatry. 2006 Oct;67(10):1542-5017107245
Cites: Pharm World Sci. 2007 Jun;29(3):126-3017333501
Cites: Ann Clin Psychiatry. 2008 Jan-Mar;20(1):15-2018297582
Cites: Curr Med Res Opin. 2008 Aug;24(8):2271-8218588748
Cites: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-20418948162
Cites: CNS Drugs. 2009;23(3):261-919320534
Cites: Clin Ther. 2009 Mar;31(3):492-50219393840
Cites: BMC Psychiatry. 2009;9:2419445700
Cites: CNS Drugs. 2009 Aug;23(8):649-5919594194
Cites: Schizophr Bull. 2010 Jan;36(1):71-9319955390
Cites: Hum Psychopharmacol. 2010 Mar;25(2):103-1520196185
Cites: BMC Psychiatry. 2010;10:2620334680
Cites: Pharmacopsychiatry. 2010 Jun;43(4):122-920309809
Cites: Expert Rev Neurother. 2010 Jul;10(7):1131-4120586693
Cites: J Clin Psychopharmacol. 2011 Feb;31(1):120-221192155
Cites: Arch Gen Psychiatry. 2000 Jun;57(6):553-910839333
PubMed ID
22996616 View in PubMed
Less detail